AJNA Biosciences

Led by industry pioneers who filed first-ever cannabis patent & brought a cannabidiol company to IPO
Powered by world-class scientists from Harvard Medical, Johns Hopkins, and NYU
Leading a new frontier in the $678B pharmaceutical industry
Phase 2 trial for Psilocybin-based antidepressant drug planned for early 2025
Phase 2 trial for CBD-based Autism Spectrum Disorder drug planned for late 2024
2 botanical drug candidates in pipeline for FDA approval with additional drugs in discovery
Green process with IP for solventless extraction methods

VC-Backed
Raised $250K or more from a venture firm, Repeat Founder
Founder has started a previous company funded with $2M+, Joel Stanley CEO & Co-FounderLeader in botanical drug innovation and CBD industry trailblazer. Scaled CBD category leader Charlotte's Web from 0 to IPO with $75M in annual revenue. Former Chairman at Charlotte’s Web., Orrin DevinskyMD, Chief Medical AdvisorDistinguished neurologist specializing in epilepsy & behavioral disorders. Renowned Professor of Neurology, Neurosurgery, & Psychiatry at NYU School of Medicine. Board Director of the Epilepsy Foundation & Chairman of the Medical Advisory Board for Tilray, Scott HansenVP, Lab Operations & QualityPharmaceutical operations expert. Specialist in quality systems and driving market advancement in cannabis and fungi industries. Former VP of Quality & Regulatory Affairs at Agricor/Botanacor, also Director of Quality and R&D at Charlotte’s Web & Sandoz., Bob JudgeVP, FinanceFinance executive with extensive leadership experience. Former CFO & COO at Timberline Industries & CEO at Lane Industries & Lane Pursuits, overseeing private equity & venture capital investments. KPMG alumnus, CPA, MBA from the University of Connecticut.